
    
      After being informed about the study and potential risks, all patients giving written
      informed consent will undergo a 1-week screening period to determine eligibility for study
      entry.

      At week 0, patients who meet the eligibility requirements will be randomized in a
      double-blind manner (participant and investigator) in a 1:1 ratio to Febuxostat (80 mg, once
      daily) or Placebo (once daily) in patients with Type 2 Diabetes Mellitus and Stage 3 Chronic
      Kidney Disease (Estimated Glomerular Filtration Rate 31:59).
    
  